Beranda › Dermatitis Atopik (Eksim) › Indiana
Uji klinis Dermatitis Atopik (Eksim) di Indiana
9 studi untuk Dermatitis Atopik (Eksim) mencari peserta di lokasi di Indiana.
Kota di Indiana
Teks studi resmi (Bahasa Inggris)
Ph 1a/1b Single Ascending Dose and Multiple Ascending Dose Study of ARQ-234
- Clinical Site 106, Plainfield
Menerima pesertaFase 1Sukarelawan sehat diterima
Usia 18 hingga 65 · Semua jenis kelamin · Diperbarui 29 Sep 2026 · NCT07453602Study of ENV-294 in Adults With Moderate-to-Severe Atopic Dermatitis
- Enveda Investigative Site, Clarksville
- Enveda Investigative Site, New Albany
- Enveda Investigative Site, West Lafayette
Menerima pesertaFase 2
Usia 18 hingga 75 · Semua jenis kelamin · Diperbarui 25 Sep 2026 · NCT07298395A Long-term Study of the Medicine Called Abrocitinib in Children Aged 2 Years and Older With Moderate to Severe Eczema
- Dawes Fretzin Clinical Research Group, LLC, Indianapolis
Menerima pesertaFase 3
Usia 2 hingga 11 · Semua jenis kelamin · Diperbarui 25 Sep 2026 · NCT06807281A Phase 2b Study of the Effects of Camoteskimab in Adults With Moderate-to-Severe Atopic Dermatitis
- DS Research of Southern Indiana,LLC, Clarksville
- Dawes Fretzin Clinical Research Group, LLC, Indianapolis
Menerima pesertaFase 2
Usia 18 hingga 65 · Semua jenis kelamin · Diperbarui 28 Agu 2026 · NCT07599813A Phase 2b Dose-Ranging Study to Evaluate the Efficacy and Safety of ENV-294 in Adults With Moderate-to-Severe Atopic Dermatitis
- Enveda Investigative Site, Indianapolis
- Enveda Investigative Site, Plainfield
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 6 Agu 2026 · NCT07643766A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis
- Dawes Fretzin /ID# 265097, Indianapolis
Menerima pesertaFase 3
Usia 2 hingga 11 · Semua jenis kelamin · Diperbarui 6 Agu 2026 · NCT06461897A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab
- Options Research Group /ID# 264564, West Lafayette
Menerima pesertaFase 3
Usia 18 hingga 63 · Semua jenis kelamin · Diperbarui 6 Jul 2026 · NCT06389136A Study To Learn About Two Study Medicines (PF-07275315 And PF-07264660) In People Who Have Moderate To Severe Atopic Dermatitis
- Dawes Fretzin Clinical Research Group, LLC, Indianapolis
- Southern Indiana Clinical Trials, New Albany
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 4 Mei 2026 · NCT05995964Real-world Experience Using Nemolizumab in the Treatment of Moderate-to-Severe Atopic Dermatitis in Adolescents & Adults
- Galderma Investigational Site 8142, Indianapolis
- Galderma Investigational Site 7083, West Lafayette
Menerima pesertaStudi observasional
Usia 12 ke atas · Semua jenis kelamin · Diperbarui 13 Mar 2026 · NCT06988605Dari ClinicalTrials.gov, data diambil 5 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.